Cargando…

Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX(®) HS, a new highly sensitive assay for the MassARRAY(®) System

Increased early detection and personalized therapy for lung cancer have coincided with greater use of minimally invasive sampling techniques such as endobronchial ultrasound-guided biopsy (EBUS), endoscopic ultrasound-guided biopsy (EUS), and navigational biopsy, as well as thin needle core biopsies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sutton, Bobbie C., Birse, Ryan T., Maggert, Kevin, Ray, Tammy, Hobbs, Jessica, Ezenekwe, Amobi, Kazmierczak, Jason, Mosko, Michael, Kish, Joan, Bullock, Andrew, Shi, Zonggao, Stack, M. Sharon, Irwin, Darryl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604939/ https://www.ncbi.nlm.nih.gov/pubmed/28926605 http://dx.doi.org/10.1371/journal.pone.0183715

Ejemplares similares

Screening of genetic alterations related to non-syndromic hearing loss using MassARRAY iPLEX® technology
por: Svidnicki, Maria Carolina CCosta CMelo, et al.
Publicado: (2015)

Whole-Genome Sequencing and iPLEX MassARRAY Genotyping Map an EMS-Induced Mutation Affecting Cell Competition in Drosophila melanogaster
por: Lee, Chang-Hyun, et al.
Publicado: (2016)

A six-member SNP assay on the iPlex MassARRAY platform provides a rapid and affordable alternative for typing major African Staphylococcus aureus types
por: Nyasinga, Justin, et al.
Publicado: (2019)

Screening of PAH Common Mutations in Chinese Phenylketonuria Patients Using iPLEX MALDI-TOF MS
por: Yan, Yousheng, et al.
Publicado: (2020)

Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients
por: Dymerska, D, et al.
Publicado: (2011)

Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling
por: Chua, Eng Wee, et al.
Publicado: (2016)

Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use
por: Shi, Zonggao, et al.
Publicado: (2022)

NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
por: Yang, Tianyou, et al.
Publicado: (2019)

The predictive value of KRAS and NRAS mutations in metastatic colorectal cancer
por: Eshraghi, Abbas, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer patients in 2015
por: Jouini, Raja, et al.
Publicado: (2019)

To PLEX or Not to PLEX for Amiodarone-Induced Thyrotoxicosis
por: Ahuja, Tania, et al.
Publicado: (2023)

KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan
por: Awidi, Muhammad, et al.
Publicado: (2019)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
por: Gökmen, İvo, et al.
Publicado: (2023)

MassArray analysis of genomic susceptibility variants in ovarian cancer
por: Verma, Sonali, et al.
Publicado: (2020)

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer
por: Sorah, Jonathan D, et al.
Publicado: (2022)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2016)

KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute
por: Kim, Yonggoo, et al.
Publicado: (2020)

Clinicopathological characteristics and mutational profile of KRAS and NRAS in Tunisian patients with sporadic colorectal cancer
por: OUNISSI, Donia, et al.
Publicado: (2021)

KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer
por: Saharti, Samah
Publicado: (2022)

High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE ‐ hypermutated colorectal cancers
por: Favre, Loetitia, et al.
Publicado: (2022)

KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
por: Vidal-Cruchez, Olivia, et al.
Publicado: (2023)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study
por: Negru, Serban, et al.
Publicado: (2014)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

Analysis of PTEN Methylation Patterns in Soft Tissue Sarcomas by MassARRAY Spectrometry
por: Yin, Liang, et al.
Publicado: (2013)

Diferencias Clínicas de las mutaciones KRAS y NRAS en pacientes con cáncer colorrectal : /
por: Gudiño Cobos, Luis Omar
Publicado: (2015)

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
por: Kriegsmann, Mark, et al.
Publicado: (2015)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
por: Geredeli, Caglayan, et al.
Publicado: (2018)

KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2019)

Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants
por: Alcantara, Krizelle Mae M., et al.
Publicado: (2019)

Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review
por: Abuzneid, Yousef S., et al.
Publicado: (2021)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
por: Martianov, Aleksandr S., et al.
Publicado: (2023)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study
por: Momenzadeh, Hooria, et al.
Publicado: (2018)

Association of KRAS and NRAS gene polymorphisms with Wilms tumor risk: a four-center case-control study
por: Fu, Wen, et al.
Publicado: (2019)

Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer
por: Franczak, Claire, et al.
Publicado: (2020)

Mutation status and prognostic value of KRAS and NRAS mutations in Moroccan colon cancer patients: A first report
por: El agy, Fatima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kpcdi5pp6p010h93d39uhqoc43